Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Innovation is the core development strategy. we have focused our R&D efforts in antineoplastic drugs, surgery medications, and medicines that treat autoimmune diseases, metabolic diseases and cardiovascular diseases. Hengrui Pharma has been on the Pharma Exec’s annual listing of the top 50 global pharmaceutical companies for the sixth consecutive year. Hengrui Pharma ranked 24th among the top 1,000 global pharma companies announced by the Torreya in 2021. Hengrui Pharma ranked 8th in the "Top 25 global pharma companies by pipeline size " selected by Citeline in 2024.

Innovation is the core of Hengrui’s development strategy. Hengrui spent more than 5 billion USD (nearly 40 billion RMB) in R&D in recent years .We have built a large-scale, professional, and comprehensive innovative drug research staff of more than 5,000 people. Fourteen R&D centers were built around the world and several subsidiaries were established in the US, EU, Australia, and Japan. Hengrui Pharma has 14 in-house developed innovative products and 2 in-licensed innovative products marketed in China , more than 90 innovative candidates in the R&D stage and nearly 20 innovative products under clinical development around the world. As of 2023, 2389 patent applications have been submitted, with 545 patents granted in China and 667 patents granted worldwide, such as the US, EU, and Japan.

Internationalization is also an important development strategy of Hengrui. By the end of 2023, Hengrui’s products have entered more than 40 countries, and will continue to accelerate global market development, focusing on emerging markets. Hengrui has established manufacturing facilities all over the country . All of its exported products meet or exceed the standards specified in the European Union and US Pharmacopoeia. We have exported injections on a large scale to the US, EU, and Japan markets. Through our international partners, Hengrui has obtained nearly 20 registration approvals including injections, oral preparations and inhalation anesthetics in the EU, US and Japan to benefit more patients around the world. We actively facilitate the transformation of our R&D findings through international collaboration, resulting in 11 overseas authorizations of innovative drugs. These include a €1.4 billion authorization partnership with the multinational giant Merck and a licensing deal worth up to US$6 billion with the U.S.-based Hercules for the GLP-1 product portfolio of HRS-7535, HRS9531, and HRS-4729, in which we will acquire 19.9% of the company’s shares.

Hengrui will continue its engagement in the innovation and development of treatments for various diseases spanning oncology, metabolic diseases, autoimmune diseases, cardiovascular diseases, and other therapeutic areas to benefit patients globally.